Investment
Features
FeesSafety
Academy
More
Pluang+

AI cloud startup Lambda plans $4B raise ahead of 2027 IPO at $14.5B valuation

Market News
06 Oct 2026
TechCrunch
View Source
Bullish
AI cloud startup Lambda plans $4B raise ahead of 2027 IPO at $14.5B valuation

AI cloud computing startup Lambda is raising up to $4 billion at a $14.5 billion valuation in what could be its final private funding round before a planned IPO in 2027. The company’s backlog surged from $15 billion to $50 billion recently, largely due to a $35 billion contract with AI firm Anthropic. While demand for GPU capacity remains strong, Lambda faces challenges in funding costly data center expansions amid tighter lending conditions. This capital raise aims to strengthen Lambda’s position and valuation ahead of its delayed IPO, joining other Nvidia-backed cloud firms preparing to go public.

Lambda AI computing startup is raising $4 billion before a planned IPO. For readers following Technology stocks, here is Pluang's market snapshot as of Oct 07, 2026 03:03 WIB: 93 of 150 Technology-sector US stocks rose, 56 fell. Notable movers include Shopify Inc. at USD 160.07 (+5.73%, 98% Sell), Asana Inc. at USD 9.09 (+5.45%, 100% Buy), and Expensify Inc. at USD 2.36 (+4.89%, 100% Buy).

More News

Stryker stock drops 8.8% on unresolved manufacturing issues despite strong growth outlook

Stryker stock drops 8.8% on unresolved manufacturing issues despite strong growth outlook

Stryker experienced an 8.8% stock drop on September 8, 2026, wiping out over $10 billion in market value due to ongoing manufacturing problems that were thought resolved. Truist Financial lowered its price target from $340 to $310, reflecting concern...

Market News
Neutral
1 hour ago
Bank OZK to report Q3 2026 earnings on Oct 20 amid Citigroup's Sell rating at $45.59

Bank OZK to report Q3 2026 earnings on Oct 20 amid Citigroup's Sell rating at $45.59

Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...

Company Fundamentals
Neutral
1 hour ago
Scotiabank raises Pfizer price target to $33, signaling 20.9% potential gain.

Scotiabank raises Pfizer price target to $33, signaling 20.9% potential gain.

Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...

Analyst Insights
Bullish
2 hours ago
Citigroup raises AstraZeneca price target after strong clinical trial results

Citigroup raises AstraZeneca price target after strong clinical trial results

Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...

Analyst Insights
Bullish
2 hours ago
Devon Energy shares seen rising 40% as analyst sets $67 price target amid asset sale pressures.

Devon Energy shares seen rising 40% as analyst sets $67 price target amid asset sale pressures.

An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App